These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 498695)

  • 1. Naphthoxylactic acid after single and long-term doses of propranolol.
    Walle T; Conradi EC; Walle UK; Fagan TC; Gaffney TE
    Clin Pharmacol Ther; 1979 Nov; 26(5):548-54. PubMed ID: 498695
    [No Abstract]   [Full Text] [Related]  

  • 2. Measurement of naphthoxylactic and naphtoxyacetic acid in human plasma following propranolol administration.
    Pritchard F; Schneck D; Hayes A
    Res Commun Chem Pathol Pharmacol; 1979 Feb; 23(2):279-86. PubMed ID: 461953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. O-methylated catechol-like metabolites of propranolol in man.
    Walle T; Conradi EC; Walle UK; Gaffney TE
    Drug Metab Dispos; 1978; 6(4):481-7. PubMed ID: 28930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of naphthoxylactic acid, a major metabolite of propranolol in plasma in man.
    Easterling DE; Walle T; Conradi EC; Gaffney TE
    J Chromatogr; 1979 Mar; 162(3):439-45. PubMed ID: 528611
    [No Abstract]   [Full Text] [Related]  

  • 5. Propranolol, propranolol glucuronide, and naphthoxylactic acid in breast milk and plasma.
    Smith MT; Livingstone I; Hooper WD; Eadie MJ; Triggs EJ
    Ther Drug Monit; 1983; 5(1):87-93. PubMed ID: 6845404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective induction of propranolol metabolism by smoking: additional effects on renal clearance of metabolites.
    Walle T; Walle UK; Cowart TD; Conradi EC; Gaffney TE
    J Pharmacol Exp Ther; 1987 Jun; 241(3):928-33. PubMed ID: 3598909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic propranolol administration during pregnancy. Maternal pharmacokinetics.
    Smith MT; Livingstone I; Eadie MJ; Hooper WD; Triggs EJ
    Eur J Clin Pharmacol; 1983; 25(4):481-90. PubMed ID: 6653642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propranolol metabolism in normal subjects: association with sex steroid hormones.
    Walle T; Walle K; Mathur RS; Palesch YY; Conradi EC
    Clin Pharmacol Ther; 1994 Aug; 56(2):127-32. PubMed ID: 8062488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variable first-pass elimination of propranolol following single and multiple oral doses in hypertensive patients.
    Wargin WA; Sawchuk RJ; McBride JW; McCoy HG; Rylander ML
    Eur J Drug Metab Pharmacokinet; 1982; 7(3):183-9. PubMed ID: 7173272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparative pharmacokinetic studies on the relative biologic availability of two propranolol preparations in patients with steady state essential hypertension].
    Rostock G; Faulhaber HD; Gohlke HR; Prehm C
    Pharmazie; 1986 Apr; 41(4):258-60. PubMed ID: 3725870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Propranolol in pregnancy three year prospective study.
    Livingstone I; Craswell PW; Bevan EB; Smith MT; Eadie MJ
    Clin Exp Hypertens B; 1983; 2(2):341-50. PubMed ID: 6872291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of diltiazem versus cimetidine on propranolol metabolism.
    Tateishi T; Ohashi K; Fujimura A; Ebihara A
    J Clin Pharmacol; 1992 Dec; 32(12):1099-104. PubMed ID: 1487547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and identification of 3-(4-hydroxy-1-naphthoxy)lactic acid as a metabolite of propranolol in the rat, in man, and in the rat liver 9000 g supernatant fraction.
    Talaat RE; Nelson WL
    Drug Metab Dispos; 1986; 14(2):202-7. PubMed ID: 2870895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propranolol in hypertension: a dose-response study.
    Galloway DB; Glover SC; Hendry WG; Logie AW; Petrie JC; Smith MC; Lewis JA; Simpson WT
    Br Med J; 1976 Jul; 2(6028):140-2. PubMed ID: 776351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Massive propranolol metabolite retention during maintenance hemodialysis.
    Stone WJ; Walle T
    Clin Pharmacol Ther; 1980 Oct; 28(4):449-55. PubMed ID: 7408404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Propranolol therapy in essential hypertension. Observations on predictability of therapeutic response.
    Hansson L; Zweifler AJ; Julius S; Ellis CN
    Int J Clin Pharmacol; 1974 Sep; 10(2):79-89. PubMed ID: 4448555
    [No Abstract]   [Full Text] [Related]  

  • 17. [Propranolol therapy in hypertension].
    Krediet RT
    Ned Tijdschr Geneeskd; 1978 May; 122(21):761-5. PubMed ID: 349413
    [No Abstract]   [Full Text] [Related]  

  • 18. Pathophysiologic and pharmacokinetic determinants of the antihypertensive response to propranolol.
    Esler M; Zweifler A; Randall O; DeQuattro V
    Clin Pharmacol Ther; 1977 Sep; 22(3):299-308. PubMed ID: 330078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Action of increasing doses of DL-propranolol on behavior of arterial pressure and plasma renin activity (PRA)].
    Cerasola G; Morici ML; Amico LM; Biondo S
    Boll Soc Ital Cardiol; 1978; 23(12):2023-34. PubMed ID: 397834
    [No Abstract]   [Full Text] [Related]  

  • 20. [Experiences with propranolol (Obsidan25) in hypertension therapy in pregnancy].
    Peiker G; Siegert C; Glöckner R; Völkner E; Traeger A
    Pharmazie; 1985 Sep; 40(9):645-7. PubMed ID: 4070348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.